SynthesisInternational urogynecology journal2012
Solifenacin for overactive bladder: a systematic review and meta-analysis.
Synthesis in International urogynecology journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04693897 (To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines.International urogynecology journal · 2019Pooled it
- Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Archives of gerontology and geriatricsPooled it
- Effectiveness of Solifenacin for Managing of Bladder Spasms in Patients With Urethroplasty.American journal of men's health · 2017Trial
- Long-term efficacy and safety of solifenacin, mirabegron, and their combination for overactive bladder: a systematic review.Frontiers in pharmacology · 2026Review
- Evaluation of Small-Molecule Candidates as Modulators of M-Type KInternational journal of molecular sciences · 2025Review
- Peroneal electric transcutaneous neuromodulation versus solifenacin in the treatment of the overactive bladder wet.Central European journal of urology · 2025Article
- The Effectiveness in Activating M-Type KInternational journal of molecular sciences · 2021Article
- Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol.BMC complementary medicine and therapies · 2020Article
- Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.Movement disorders : official journal of the Movement Disorder Society · 2019Review
- The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women.Frontiers in cellular and infection microbiology · 2019Review
- Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.Journal of market access & health policy · 2018Article
- Solifenacin linked QT interval prolongation and torsades de pointes.Therapeutic advances in drug safety · 2017Article
- Article
- Does conservative management really benefit patients with OAB?Current urology reports · 2012Article
- Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis.Urology annalsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the efficacy and safety of solifenacin for treating overactive bladder. Randomized controlled trials (RCTs) were identified and extracted from MEDLINE, Embase, and CENTRAL. The quality of the included RCTs was assessed using the Jadad score, and heterogeneity was analyzed using the chi-squared test. The data of the included RCTs were collected, extracted, and assessed by our protocol. A total of nine RCTs were identified from the search strategy. Compared with the placebo and tolterodine treatments, both short-term (mostly 12-week) trials indicated that solifenacin significantly reduced urgency episodes, micturitions, and incontinence episodes per 24 h. Compared with the solifenacin (5 mg) group, the solifenacin (10 mg) group was significantly better in terms of the number of micturitions per 24 h. With regard to adverse effects, the patients treated with solifenacin had significantly higher rates of constipation and blurred vision than patients treated with tolterodine. The solifenacin therapy was not inferior to tolterodine in terms of efficacy profiles and had a similar incidence of overall adverse events compared with tolterodine treatment. Solifenacin (5 mg) is thus a recommended dose because of its reported balance between efficacy and acceptable tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.